Financial Daily from THE HINDU group of publications
Friday, Aug 13, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Markets - Stock Markets


Orchid Chem jumps on talk of FCCB issue

Our Bureau

Chennai , Aug. 12

THE Orchid Chemicals & Pharmaceuticals share gained 14.06 per cent to close at Rs 201.65 amid market talk that the company was about to place foreign currency convertible bonds (FCCBs) at a premium to the prevailing price, and is also close to an out-licensing deal for a molecule.

A company official had told Business Line in mid-July that they had suspended the proposed $75 million FCCB issue in view of uncertainty in the global capital markets.

The company spokesperson today said that Orchid continued to keep the FCCB option open, adding that there had been no change in status over the last month. The spokesperson also said Orchid has started "preliminary discussions" with overseas companies for possible out-licensing of its molecule. The anti-diabetic molecule has completed the first phase of clinical trials in Europe and is currently being put through the second phase.

The stock has increased 16.09 per cent from the previous week's close of Rs 173.70.

More Stories on : Stock Markets

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Fund of funds for efficient asset allocation


HDFC Mutual to launch 2 equity-linked schemes
ULIPs vs MFs: AMFI calls for even field
UltraTech CemCo to be listed by August 16
Bears prevail
Radico Khaitan hits 52-week high on revamp proposals
Orchid Chem jumps on talk of FCCB issue
Sintex India shines on FII buying
Indices tumble further on inflation worries
Crew B.O.S. to raise Rs 14 cr thru IPO



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line